0.9277
price down icon0.49%   -0.0046
after-market Handel nachbörslich: .91 -0.0177 -1.91%
loading
Schlusskurs vom Vortag:
$0.9323
Offen:
$0.93
24-Stunden-Volumen:
1.65M
Relative Volume:
0.43
Marktkapitalisierung:
$150.85M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
23.19
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
-4.41%
1M Leistung:
-30.77%
6M Leistung:
-79.34%
1J Leistung:
-88.58%
1-Tages-Spanne:
Value
$0.8989
$0.9596
1-Wochen-Bereich:
Value
$0.8842
$0.9967
52-Wochen-Spanne:
Value
$0.591
$8.23

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Name
Firmenname
Ironwood Pharmaceuticals Inc
Name
Telefon
617-621-7722
Name
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Name
Mitarbeiter
253
Name
Twitter
@ironwoodpharma
Name
Nächster Verdiensttermin
2025-02-21
Name
Neueste SEC-Einreichungen
Name
IRWD's Discussions on Twitter

Vergleichen Sie IRWD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
IRWD
Ironwood Pharmaceuticals Inc
0.9277 150.85M 400.57M 9.21M 146.36M 0.04
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
158.06 68.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.38 47.71B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.63 46.12B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.39 18.55B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
298.70 13.40B 2.76B 1.11B 898.10M 22.77

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-15 Herabstufung Jefferies Buy → Hold
2025-04-15 Herabstufung Wells Fargo Overweight → Equal Weight
2025-04-14 Herabstufung Citizens JMP Mkt Outperform → Mkt Perform
2024-09-09 Eingeleitet Leerink Partners Market Perform
2024-08-08 Herabstufung CapitalOne Overweight → Equal Weight
2024-01-17 Eingeleitet Craig Hallum Buy
2023-12-14 Eingeleitet Wells Fargo Overweight
2023-11-09 Eingeleitet Jefferies Buy
2023-09-28 Eingeleitet JMP Securities Mkt Outperform
2022-09-02 Eingeleitet CapitalOne Overweight
2022-04-22 Eingeleitet Piper Sandler Overweight
2020-09-30 Herabstufung Wells Fargo Overweight → Equal Weight
2020-06-17 Eingeleitet Northland Capital Outperform
2019-07-10 Fortgesetzt Credit Suisse Neutral
2019-03-27 Hochstufung Morgan Stanley Underweight → Equal-Weight
2019-02-25 Hochstufung H.C. Wainwright Sell → Neutral
2019-01-24 Hochstufung JP Morgan Underweight → Neutral
2018-11-07 Herabstufung Credit Suisse Outperform → Neutral
2018-11-07 Herabstufung JP Morgan Neutral → Underweight
2018-07-23 Eingeleitet H.C. Wainwright Sell
2018-05-09 Herabstufung Morgan Stanley Equal-Weight → Underweight
2018-01-05 Herabstufung BofA/Merrill Buy → Underperform
2017-12-06 Herabstufung Mizuho Buy → Neutral
2017-07-21 Herabstufung JP Morgan Overweight → Neutral
2017-05-03 Eingeleitet Wells Fargo Outperform
2017-04-07 Bestätigt Mizuho Buy
2017-02-22 Bestätigt Barclays Equal Weight
2016-11-04 Bestätigt Mizuho Buy
2016-10-24 Bestätigt Wedbush Neutral
2016-10-10 Bestätigt Mizuho Buy
2016-09-27 Bestätigt WallachBeth Hold
Alle ansehen

Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten

pulisher
May 01, 2025

Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

May 01, 2025
pulisher
Apr 30, 2025

Ironwood Pharmaceuticals to Participate in The Citizens Life Sci - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire

Apr 30, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025 - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise - MSN

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - ADVFN

Apr 25, 2025
pulisher
Apr 25, 2025

Ironwood Pharmaceuticals Reiterates Full-Year 2025 Guidance and Raises Adjusted EBITDA - TradingView

Apr 25, 2025
pulisher
Apr 23, 2025

Ironwood Pharmaceuticals to Present Real-World Data at Digestive - GuruFocus

Apr 23, 2025
pulisher
Apr 22, 2025

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - itemonline.com

Apr 22, 2025
pulisher
Apr 18, 2025

Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN

Apr 18, 2025
pulisher
Apr 18, 2025

Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com

Apr 18, 2025
pulisher
Apr 17, 2025

Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN

Apr 17, 2025
pulisher
Apr 16, 2025

Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Top Midday Decliners - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood to considers merger opportunities after FDA setback - The Business Journals

Apr 14, 2025
pulisher
Apr 14, 2025

Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Faces Financial Uncertainty as Price Target is S - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | IRWD Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Faces Financial Uncertainty as Price Target is Slashed | IRWD Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood: FDA nay on PK means another apraglutide study - BioWorld MedTech

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - BioSpace

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial - MarketWatch

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals (IRWD) Considers Strategic Options Afte - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Says FDA to Require Additional Phase 3 Trial for Apraglutide; to Explore Strategic Options - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma stock down on regulatory hurdle (IRWD:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood Pharma Provides Update On Apraglutide; Plans Strategic Alternatives - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Followin - GuruFocus

Apr 14, 2025

Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ironwood Pharmaceuticals Inc-Aktie (IRWD) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Silver Ronald
Principal Accounting Officer
Feb 10 '25
Sale
1.76
12,048
21,204
279,655
Shetzline Michael
SVP, CMO, Head-Res&Drug
Feb 10 '25
Sale
1.76
41,269
72,633
554,007
John Minardo
Chief Legal Officer
Feb 10 '25
Sale
1.76
38,938
68,531
408,132
Martini Gregory S.
Chief Financial Officer
Feb 10 '25
Sale
1.76
12,052
21,212
183,810
$31.40
price down icon 1.20%
$9.65
price down icon 1.03%
$107.98
price down icon 0.70%
$8.59
price down icon 0.69%
$109.75
price up icon 0.06%
$298.70
price up icon 1.39%
Kapitalisierung:     |  Volumen (24h):